Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.40 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | MELK | Q14680 | 4/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5049272 | 0.83 | ERN1 (0.39) | CRHR1GRM5MELKSMN1; SMN2KDM4E | |
| SCHEMBL14472676 | 0.74 | GPBAR1 (0.37) | IRAK4CRHR1MAPT | |
| SCHEMBL5046238 | 0.69 | ALDH1A1 (0.47) | PARP1MEN1KMT2AHTR1AADRA1D | |
| SCHEMBL5043548 | 0.68 | IRAK4 (0.40) | IRAK4PARP1ATMTP53GAA | |
| SCHEMBL2392414 | 0.65 | ALDH1A1 (0.45) | CRHR1MEN1KMT2ATP53GAA | |
| SCHEMBL3041872 | 0.65 | CNR1 (0.40) | GAAMAPTALDH1A1 | |
| SCHEMBL20815947 | 0.65 | MELK (0.55) | MELK | |
| SCHEMBL3043041 | 0.64 | ERN1 (0.46) | — | |
| SCHEMBL24956766 | 0.64 | HTR1A (0.51) | PARP1MEN1KMT2AHTR1AADRA1D | |
| SCHEMBL5623905 | 0.62 | CRHR1 (0.36) | CRHR1GAAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765030-B2 | Benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2017-09-19 | — | — | US | disclosed |
| US-9765030-B2 | Benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2017-09-19 | — | — | US | disclosed |
| US-9765030-B2 | Benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2017-09-19 | — | — | US | disclosed |
| EP-1981342-B1 | SELECTIVE BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | REDDYS LAB LTD DR (IN) | 2016-11-30 | — | — | EP | disclosed |
| EP-1981342-B1 | SELECTIVE BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | REDDYS LAB LTD DR (IN) | 2016-11-30 | — | — | EP | disclosed |
| US-20140134235-A1 | NOVEL BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2014-05-15 | — | — | US | disclosed |
| US-20140134235-A1 | NOVEL BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2014-05-15 | — | — | US | disclosed |
| US-20140134235-A1 | NOVEL BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2014-05-15 | — | — | US | disclosed |
| US-8604055-B2 | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2013-12-10 | — | — | US | disclosed |
| EP-1981342-A1 | SELECTIVE BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | Reddy US Therapeutics, Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007075194-A1 | SELECTIVE BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | REDDY US THERAPEUTICS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007075194-A1 | SELECTIVE BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | REDDY US THERAPEUTICS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-01-18 | — | — | US | disclosed |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-01-18 | — | — | US | disclosed |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140134235-A1 | NOVEL BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS | CETP, NPC1, DBI | IRAK4 1344/4885CRHR1 4802/4885PARP1 3077/4885 |
| US-20070015758-A1 | Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors | CETP, NPC1, DBI | IRAK4 1344/4885CRHR1 4802/4885PARP1 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.